Author(s): MAHONEY, KATHLEEN M. ; JACOBUS, SUSANNA ; BHATT, RUPAL S. ; SONG, JIAXI ; CARVO, INGRID ; CHENG, SU-CHUN ; SIMPSON, MEKAILAH ; André Poisl Fay ; PUZANOV, IGOR ; MICHAELSON, M. DROR ; ATKINS, MICHAEL B. ; MCDERMOTT, DAVID F. ; SIGNORETTI, SABINA ; CHOUEIRI, TONI K.
Date: 2022
Persistent ID: https://hdl.handle.net/10923/21639
Origin: Oasisbr
Submitted by Biblioteca Suporte PUCRS (biblioteca.suporte@pucrs.br) on 2022-05-17T14:47:11Z No. of bitstreams: 2 Phase_2_Study_of_Bevacizumab_and_Temsirolimus_After_VEGFR_TKI_in_Metastatic_Renal_Cell_Carcinoma.pdf: 2241166 bytes, checksum: 424ef1f51599b0569c34e5742c437a68 (MD5) Phase_2_Study_of_Bevacizumab_and_Temsirolimus_After_VEGFR_TKI_in_Metastatic_Renal_Cell_Carcinoma.pdf: 2241166 bytes, checksum: 424ef1f51599b0569c34e5742c437a68 (MD5)
Made available in DSpace on 2022-05-17T14:47:11Z (GMT). No. of bitstreams: 2 Phase_2_Study_of_Bevacizumab_and_Temsirolimus_After_VEGFR_TKI_in_Metastatic_Renal_Cell_Carcinoma.pdf: 2241166 bytes, checksum: 424ef1f51599b0569c34e5742c437a68 (MD5) Phase_2_Study_of_Bevacizumab_and_Temsirolimus_After_VEGFR_TKI_in_Metastatic_Renal_Cell_Carcinoma.pdf: 2241166 bytes, checksum: 424ef1f51599b0569c34e5742c437a68 (MD5) Previous issue date: 2016
